Trials / Completed
CompletedNCT04885998
AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)
A Phase 1b Study Evaluating the Safety and Efficacy of AMG 757 in Combination With AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety, tolerability, and recommended phase 2 target dose of tarlatamab in combination with AMG 404.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tarlatamab | Tarlatamab will be administered as an intravenous (IV) infusion. |
| DRUG | AMG 404 | AMG 404 will be administered as an intravenous (IV) infusion. |
Timeline
- Start date
- 2021-09-27
- Primary completion
- 2023-07-12
- Completion
- 2024-09-11
- First posted
- 2021-05-13
- Last updated
- 2025-09-29
- Results posted
- 2024-10-15
Locations
17 sites across 6 countries: United States, Austria, Belgium, Japan, Singapore, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04885998. Inclusion in this directory is not an endorsement.